<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080054</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-0218</org_study_id>
    <nct_id>NCT00080054</nct_id>
  </id_info>
  <brief_title>A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas</brief_title>
  <official_title>Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Temozolomide for Treatment of Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out about the safety of adding the investigational drug&#xD;
      motexafin gadolinium to a standard course of chemotherapy with temozolomide for patients with&#xD;
      malignant glioma. Secondly, the study will determine how many patients will respond to this&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>Glioma</condition>
  <condition>Glioblastoma</condition>
  <condition>Astrocytoma</condition>
  <condition>Oligodendroglioma</condition>
  <condition>Brain Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motexafin Gadolinium Injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years old&#xD;
&#xD;
          -  Histologically confirmed diagnosis of malignant gliomas that requires systemic&#xD;
             antineoplastic treatment. Malignant glioma is defined as any of the following:&#xD;
             Glioblastoma multiforme (GBM); Anaplastic astrocytoma (AA); Anaplastic&#xD;
             oligodendroglioma; Anaplastic mixed glioma; Glioma not otherwise specified (except&#xD;
             low-grade glioma)&#xD;
&#xD;
          -  ECOG performance status score of 0, 1, or 2&#xD;
&#xD;
          -  Each patient must sign a study-specific informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Laboratory values of:&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 2000/µL&#xD;
&#xD;
          -  Platelet count &lt; 100,000/µL&#xD;
&#xD;
          -  AST or ALT &gt; 2 x the upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase &gt; 5 x ULN&#xD;
&#xD;
          -  Bilirubin &gt; 2 x ULN&#xD;
&#xD;
          -  Creatinine &gt; 2.0 mg/µL&#xD;
&#xD;
        and&#xD;
&#xD;
          -  Plan to use any additional cancer therapy (e.g., systemic, radiation, surgery) during&#xD;
             the study period&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.braintumor.org</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.pcyc.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>March 22, 2004</study_first_submitted>
  <study_first_submitted_qc>March 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2004</study_first_posted>
  <last_update_submitted>April 2, 2009</last_update_submitted>
  <last_update_submitted_qc>April 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2009</last_update_posted>
  <keyword>Malignant Glioma</keyword>
  <keyword>Glioblastoma multiforme</keyword>
  <keyword>GBM</keyword>
  <keyword>Anaplastic astrocytoma</keyword>
  <keyword>AA</keyword>
  <keyword>Anaplastic oligodendroglioma</keyword>
  <keyword>Anaplastic mixed glioma</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Brain neoplasm</keyword>
  <keyword>Glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

